Patient-specific tumor neoantigen-Major Histocompatibility Complex (MHC) complex (NeoAg-MHC)

Patient-specific tumor neoantigens presented on dendritic cell MHC molecules are unique, non-self peptides derived from somatic mutations unique to an individual's cancer (Nature, 2017). These mutations, such as single-nucleotide variants or frameshifts, produce novel protein sequences that are absent from the normal human proteome, making them ideal targets for highly specific immunotherapy (Frontiers in Immunology, 2020). Dendritic cells process these neoantigens and display them on Major Histocompatibility Complex (MHC) Class I and II molecules to prime and activate naive T cells (Science, 2015). This interaction is the cornerstone of personalized cancer vaccines, as it directs the immune system to specifically recognize and destroy malignant cells while sparing healthy tissue. Therapeutic strategies targeting these complexes include personalized mRNA vaccines, synthetic long peptides, and ex vivo-loaded dendritic cell therapies (Nature, 2017). By leveraging the high specificity of neoantigens, these treatments aim to overcome immune tolerance and generate a robust, durable anti-tumor response tailored to the individual's unique genomic landscape. This approach is particularly relevant for tumors with high mutational burdens, where the probability of identifying immunogenic neoepitopes is increased (Journal of Hematology & Oncology, 2021).

Other names

Personalized tumor neoantigensTumor-specific neoepitopesNeoepitope-HLA complexTSA-MHC complexNeoantigen-MHC complex

Induction of a polyclonal T-cell response against tumor-specific mutations through the presentation of neoepitopes on MHC molecules by dendritic cells, facilitating the recognition and lysis of tumor cells by cytotoxic T lymphocytes (Nature, 2017; Science, 2015).